Synaptic Loss in Alzheimer's Disease Pathway

Synaptic Loss in Alzheimer's Disease Pathway

Synaptic loss is the strongest neuropathological correlate of cognitive impairment in Alzheimer's disease (AD), more closely correlating with cognitive deficits than amyloid plaques or neurofibrillary tangles. This page synthesizes current understanding of synaptic degeneration in AD, from molecular mechanisms to therapeutic implications.

Overview

The synapse is the fundamental unit of neuronal communication and forms the basis of memory and learning. In AD, synapses are early and major targets of pathology, with synaptic loss beginning in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and spreading throughout connected networks as disease progresses[@selkoe2002][selkoe2002 2002, selkoe2002](https://pubmed.ncbi.nlm.nih.gov/12445539/).

Postmortem studies consistently show:

• 25-35% reduction in synaptic density in AD [cortex](/brain-regions/cortex)
• Synaptic loss correlates strongly with cognitive impairment (r > 0.8)
• Loss begins before clinical symptoms
• Continues throughout disease progression

This makes synaptic preservation a primary therapeutic goal in AD[@terry1991][terry1991 1991, Physical basis of cognitive alterations in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1853497/).

Synaptic Structure and Function

The Synaptic Architecture

...

Synaptic Loss in Alzheimer's Disease Pathway

Synaptic loss is the strongest neuropathological correlate of cognitive impairment in Alzheimer's disease (AD), more closely correlating with cognitive deficits than amyloid plaques or neurofibrillary tangles. This page synthesizes current understanding of synaptic degeneration in AD, from molecular mechanisms to therapeutic implications.

Overview

The synapse is the fundamental unit of neuronal communication and forms the basis of memory and learning. In AD, synapses are early and major targets of pathology, with synaptic loss beginning in the [entorhinal cortex](/brain-regions/entorhinal-cortex) and spreading throughout connected networks as disease progresses[@selkoe2002][selkoe2002 2002, selkoe2002](https://pubmed.ncbi.nlm.nih.gov/12445539/).

Postmortem studies consistently show:

• 25-35% reduction in synaptic density in AD [cortex](/brain-regions/cortex)
• Synaptic loss correlates strongly with cognitive impairment (r > 0.8)
• Loss begins before clinical symptoms
• Continues throughout disease progression

This makes synaptic preservation a primary therapeutic goal in AD[@terry1991][terry1991 1991, Physical basis of cognitive alterations in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1853497/).

Synaptic Structure and Function

The Synaptic Architecture

The synapse consists of:

• Presynaptic terminal: Contains synaptic vesicles, release machinery
• Postsynaptic density (PSD): Receptor scaffolds, signaling complexes
• Synaptic cleft: Neurotransmitter diffusion space
• Astrocytic processes: Metabolic support, glutamate recycling

Key Synaptic Proteins

Synaptic integrity depends on numerous proteins:

• Synaptophysin: Major synaptic vesicle protein
• PSD95: Postsynaptic scaffold ( excitatory synapses)
• Synapsin: Vesicle trafficking
• SNARE proteins: Vesicle fusion
• GluR subunits: Glutamate receptors
• NR2B/NR2A: [NMDA receptor](/entities/nmda-receptor) subunits

Mechanisms of Synaptic Loss in AD

Amyloid-Beta Synaptic Toxicity

[Aβ](/proteins/amyloid-beta) oligomers directly bind to synapses:

Prion protein (PrP^C) as receptor: Aβ oligomers bind to PrP^C, triggering Fyn kinase activation

NMDA receptor internalization: Leads to synaptic depression

AMPA receptor trafficking: Reduces synaptic responsiveness

Synaptic zinc dysregulation: Aβ disrupts zinc homeostasis at synapses

Key receptors for Aβ oligomers:

• PrP^C (cellular prion protein)
• Ephrin B2 receptor
• Lilrb2 (leukocyte immunoglobulin-like receptor B2)
• [RAGE](/entities/rage-receptor) (Receptor for Advanced Glycation Endproducts)

Tau-Mediated Synaptic Dysfunction

[Tau](/proteins/tau) contributes to synaptic loss through multiple mechanisms[liu2023 2023, Tau pathology and synaptic loss in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37178956/)[perlson2024 2024, Tau-based synaptic pathology in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38667333/):

Postsynaptic accumulation: Hyperphosphorylated tau in [dendritic spines](/mechanisms/dendritic-spines)

Synaptic protein mislocalization: Tau disrupts proper protein localization

Fyn kinase misdirection: Tau recruits Fyn to dendrites, enhancing NMDA receptor toxicity

Impaired trafficking: Tau disrupts vesicle and receptor transport

Excitotoxicity

Glutamate-mediated excitotoxicity contributes to synaptic loss[zhang2024 2024, Amyloid-β induced synaptic dysfunction through NMDA receptor trafficking](https://pubmed.ncbi.nlm.nih.gov/38734892/):

NMDA receptor overactivation: Aβ and tau promote excessive activation

Calcium influx: Triggers damaging signaling cascades

[mTOR](/mechanisms/mtor-signaling-pathway) activation: Leads to AMPA receptor internalization

Synaptic dismantling: Calpain activation degrades synaptic proteins

Synaptic Mitochondrial Dysfunction

Energy failure at synapses contributes to degeneration[yang2023 2023, Synaptic mitochondrial dysfunction in early AD](https://pubmed.ncbi.nlm.nih.gov/37005348/):

Reduced ATP: Impaired mitochondrial function

Calcium buffering failure: Exacerbates excitotoxicity

Transport defects: Reduced mitochondrial delivery to synapses

Synaptic proteins degraded: Energy-dependent maintenance fails

Neuroinflammation and Synaptic Pruning

Complement-Mediated Elimination

The [complement system](/entities/complement-system) inappropriately eliminates synapses in AD[shi2023 2023, Microglia complement C1q and C3 mediate synaptic pruning in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37855670/)[li2023 2023, Complement activation drives synaptic loss in AD mouse models](https://pubmed.ncbi.nlm.nih.gov/37612502/):

C1q tagging: Marks synapses for elimination[wang2024 2024, Complement C1q binds to synapses in AD brain](https://pubmed.ncbi.nlm.nih.gov/38325741/)

C3 activation: Opsonizes tagged synapses

Microglial phagocytosis: CR3 receptors recognize C3b[yuan2023 2023, CR3-mediated microglial phagocytosis of synapses in AD](https://pubmed.ncbi.nlm.nih.gov/37248320/)

Excessive pruning: Developmental mechanisms repurposed[hong2016 2016, hong2016](https://pubmed.ncbi.nlm.nih.gov/27019227/)

Microglial Synaptic Elimination

Activated [microglia](/cell-types/microglia-neuroinflammation) phagocytose synapses[park2023 2023, Microglial phagocytosis of synapses in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36754289/)[johnson2022 2022, A brain perivascular macrophage reveal the spatial dynamics of immune cells i...](https://pubmed.ncbi.nlm.nih.gov/35694267/):

• Synaptic stripping: Physical removal by microglia
• DAM formation: Disease-associated microglia target synapses
• [TREM2](/proteins/trem2)-dependent: TREM2 variants affect pruning

Astrocyte-Mediated Loss

Reactive [astrocytes](/entities/astrocytes) contribute to synaptic loss:

• D-Serine release: May promote excitotoxicity
• Complement release: C3 from astrocytes
• Metabolic uncoupling: Reduced support to synapses

Synaptic Signaling Dysfunction

Long-Term Potentiation (LTP) Impairment

[LTP](/mechanisms/long-term-potentiation), the cellular basis of learning, is disrupted by:

NMDA receptor dysfunction: Aβ reduces surface expression

AMPA receptor trafficking: Impaired insertion

cAMP/PKA signaling: Second messenger disruption

CaMKII activation: Reduced calcium-triggered activation

mTOR signaling: Translation control impaired

Long-Term Depression (LTD) Enhancement

LTD is paradoxically enhanced in AD:

AMPA receptor internalization: Accelerated removal

Protein phosphatase activation: Removes synaptic strength

NMDA receptor activation: Promotes internalization pathway

Synaptic Protein Degradation

Ubiquitin-proteasome and [autophagy](/entities/autophagy) systems:

• Synaptic protein turnover: Reduced
• Ubiquitin accumulation: Damaged proteins
• Autophagy impairment: Failure to clear debris
• Synaptic autophagy: Pathologically enhanced

Structural Synaptic Changes

Spine Morphology

Dendritic spines show abnormal changes[chen2020 2020, Dendritic spine degeneration and synaptic plasticity in Alzheimer′s disease](https://pubmed.ncbi.nlm.nih.gov/32083538/)[wu2024 2024, Dendritic spine remodeling in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38598712/)[smith2024 2024, Dendritic spine loss in APP/PS1 mice correlates with cognitive decline](https://pubmed.ncbi.nlm.nih.gov/38912345/):

• Reduced spine density: 25-50% loss in AD cortex[zhou2024 2024, Synaptic dysfunction in 5xFAD mouse model](https://pubmed.ncbi.nlm.nih.gov/39065432/)
• Morphological abnormalities: Stubby, thin spines
• Head diameter reduction: Smaller synaptic heads
• Filopodia-like protrusions: Immature appearance

Presynaptic Terminal Changes

Presynaptic alterations include[MISSING:compton2023](https://pubmed.ncbi.nlm.nih.gov/)[MISSING:moreno2024](https://pubmed.ncbi.nlm.nih.gov/):

• Vesicle depletion: Reduced synaptic vesicle pools
• Active zone remodeling: Release site changes
• Synaptic vesicle protein reduction: Synaptophysin loss
• Terminal degeneration: Vacuolization, loss

Subtype Vulnerability

Different synapse types show varying susceptibility:

• Excitatory (/glutamatergic): Most vulnerable
• Inhibitory (GABAergic): Relatively spared initially
• Cholinergic: Early target in basal forebrain
• Noradrenergic: Locus coeruleus degeneration

Synaptic Spread and Network Dysfunction

Network-Level Effects

Synaptic loss disrupts brain networks:

Default mode network: Early dysfunction

Salience network: Compensatory changes

Executive network: Later involvement

hippocampal circuits: Memory systems affected

Prion-Like Propagation

Pathological proteins spread trans-synaptically:

• Aβ release: From presynaptic terminals
• Tau spread: Along connected [neurons](/entities/neurons)
• Synaptic vesicle involvement: Vehicle for spread
• Network targeting: Connected regions

Genetic Factors

Synaptic Genes and AD Risk

Several synaptic genes influence AD risk:

| Gene | Function | AD Relevance |
|------|----------|-------------|
| [CLU](/genes/clusterin) | Synaptic chaperone | Risk allele affects clearance |
| [PICALM](/genes/picalm) | Clathrin-mediated endocytosis | Affects receptor trafficking |
| [BIN1](/genes/bin1) | Amphiphysin, endocytosis | Tau genetic modifier |
| [SNP29](/genes/snap29) | SNARE complex | Risk variant identified |

APOE Effects on Synapses

[APOE](/genes/apoe) ε4 particularly affects synaptic integrity:

• Impaired synaptic repair
• Reduced synaptic plasticity
• Enhanced Aβ toxicity at synapses
• Accelerated age-related loss[koffie2012 2012, koffie2012](https://pubmed.ncbi.nlm.nih.gov/22722202/)

Therapeutic Implications

Synaptic Protection Strategies

Multiple approaches aim to preserve synapses:

Anti-Aβ immunotherapy: Reduce oligomeric species

Tau-targeted therapies: Prevent synaptic tau

NMDA receptor modulators: Memantine

AMPA receptor positive modulators: Enhance transmission

Growth factors: BDNF, NGF delivery

Synaptic Restoration Approaches

Restoring lost synapses:

• Neurotrophic factors: Promote synaptogenesis
• Stem cell approaches: Replace lost neurons
• Activity-dependent plasticity: Environmental enrichment
• Small molecules: Synaptic enhancers

Failed Clinical Approaches

Many synaptic-protective strategies have failed:

• Semaglintide: GLP-1 agonist (failed in trials)
• Latrepirdine: Failed in Phase III
• Dimebolin: Failed in trials
• Etazolate: GABA modulator (/failed)

Biomarkers of Synaptic Loss

CSF Biomarkers

Cerebrospinal fluid markers:

• Neurogranin: Postsynaptic protein
• SNAP-25: Presynaptic terminal
• Synaptotagmin: Vesicle protein
• Phospho-tau/beta: Correlation with synaptic markers

PET Imaging

Emerging synaptic imaging:

• SV2A PET: Synaptic vesicle protein
• Fluoroglutamate: Excitatory synapses
• Correlation with FDG-PET: Metabolic dysfunction[mecca2020 2020, Synaptic integrity in the aging brain: CSF biomarkers and cognitive performance](https://pubmed.ncbi.nlm.nih.gov/31965016/)

Mermaid Pathway Diagram

Cross-Linking to Related Pages

• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Neuroinflammation AD Pathway](/mechanisms/neuroinflammation-ad-pathway)
• [Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
• [Neuronal Network Dysfunction in Alzheimer's](/mechanisms/neuronal-network-dysfunction-alzheimers)
• [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Synaptic Plasticity Mechanisms](/mechanisms/activity-dependent-synaptic-plasticity)

Key Findings

Synaptic loss correlates more strongly with cognitive impairment than amyloid or tau burden

Aβ oligomers bind to synaptic receptors (PrP^C,EphB2), triggering dysfunction

Tau accumulates in dendritic spines, disrupting synaptic structure

Complement-mediated synaptic pruning is pathologically activated in AD

Synaptic mitochondria are early targets, leading to energy failure

Multiple therapeutic approaches targeting synaptic protection have failed, highlighting complexity

See Also

• [CLU](/genes/clusterin)
• [PICALM](/genes/picalm)
• [BIN1](/genes/bin1)
• [SNP29](/genes/snap29)
• [APOE](/genes/apoe)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Neuroinflammation AD Pathway](/mechanisms/neuroinflammation-ad-pathway)
• [Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
• [Neuronal Network Dysfunction in Alzheimer's](/mechanisms/neuronal-network-dysfunction-alzheimers)
• [Network Oscillation Dysfunction](/mechanisms/network-oscillation-dysfunction)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Synaptic Dysfunction in Specific Brain Regions

Hippocampal Synaptic Changes

The hippocampus shows early and severe synaptic loss:

CA1 Region:

• Postsynaptic density reduction
• Schaeffer collateral degeneration
• NMDA receptor subunit changes

Dentate Gyrus:

• Mossy fiber terminal loss
• Granule cell synapse alterations
• Molecular layer changes

Cortical Synaptic Alterations

Entorhinal Cortex:

• Layer II stellate cells affected
• Perforant path origin
• Early tau pathology

Prefrontal Cortex:

• Executive function correlates
• Layer-specific loss
• Pyramidal neuron dysfunction

Basal Forebrain Cholinergic Synapses

The basal forebrain cholinergic system:

• Loss of cholinergic terminals
• Impaired neurotrophin support
• Contributes to memory deficits

Therapeutic Strategies for Synaptic Protection

Current Approaches

symptomatic Therapies:

• Acetylcholinesterase inhibitors
• NMDA receptor modulators
• Antioxidants

Disease-Modifying Approaches:

• Anti-Aβ immunotherapies
• Anti-tau approaches
• Neurotrophin enhancement

Emerging Strategies

Synaptic Preservation:

• Fyn kinase inhibitors
• NMDA receptor antagonists
• AMPA receptor modulators

Synaptic Repair:

• Synaptic protein replacement
• Neurotrophin delivery
• Stem cell therapy

Anti-inflammatory:

• Microglial modulation
• Complement inhibition
• TREM2 agonists

Synaptic Biomarkers

Fluid Biomarkers

• Neurogranin: Postsynaptic protein
• SNAP-25: Presynaptic terminal
• Synaptotagmin: Vesicle release
• PSD95: Postsynaptic density

Imaging Biomarkers

• PET synaptic density: SV2A ligands
• MRI synaptic imaging: Emerging techniques
• FDG-PET: Metabolic correlates

Synaptic Calcium Dysregulation

Calcium homeostasis is critical for synaptic function:

Normal Calcium Signaling:

• Presynaptic calcium entry triggers vesicle release
• Postsynaptic calcium initiates LTP/LTD
• Calcium buffers maintain homeostasis

AD-Related Dysregulation:

• Aβ forms calcium-permeable channels
• NMDA receptor overactivation increases influx
• Mitochondrial calcium overload
• Calpain activation

Consequences:

• Excitotoxic cell death
• Synaptic protein degradation
• Spine loss
• LTP impairment

Synaptic Protein Phosphorylation

Kinase Systems:

• CaMKII: Calcium-dependent activation
• PKA: cAMP-mediated signaling
• GSK-3β: Tau phosphorylation
• Fyn: Tyrosine kinase

Phosphatase Systems:

• PP1: Protein phosphatase 1
• PP2A: Major tau phosphatase
• Calcineurin: Calcium-dependent

Imbalance in AD:

• Hyperactive kinases
• Reduced phosphatase activity
• Abnormal protein phosphorylation
• Synaptic protein dysfunction

Synaptic Vesicle Cycle

The vesicle cycle is impaired in AD:

Stages:

Vesicle docking

Priming

Calcium-triggered fusion

Endocytosis

Recycling

AD Impairments:

• Reduced vesicle numbers
• Impaired docking
• Fusion machinery dysfunction
• Recycling defects

Postsynaptic Density Dysfunction

The PSD is a signaling hub:

PSD Components:

• PSD95: Scaffold protein
• NMDA receptors
• AMPA receptors
• Signaling enzymes

In AD:

• Reduced PSD95
• Receptor internalization
• Signaling disruption
• Scaffold breakdown

Synaptic Networks in AD

Hippocampal Circuitry

The Trisynaptic Circuit:

• Entorhinal cortex → Dentate gyrus
• Dentate gyrus → CA3
• CA3 → CA1

In AD:

• Perforant path degeneration
• CA3 mossy fiber loss
• Schaffer collateral impairment

Cortical Networks

Feedforward Circuits:

• Layer 4 → Layer 2/3
• Layer 2/3 → Layer 5

Feedback Circuits:

• Layer 5 → Layer 2/3

AD Changes:

• Reduced connectivity
• Synchronization loss
• Network fragmentation

Thalamocortical Systems

• Sensory relay disruption
• Prefrontal connections affected
• Motor cortex involvement

Synaptic Plasticity in AD

Long-Term Potentiation (LTP)

LTP is the cellular correlate of learning:

Mechanisms:

• NMDA receptor activation
• Calcium influx
• CaMKII activation
• AMPA receptor insertion

Aβ Effects:

• Inhibits LTP induction
• Reduces LTP maintenance
• Promotes LTP reversal
• Impairs consolidation

Long-Term Depression (LTD)

LTD is enhanced in AD:

Mechanisms:

• NMDA receptor activation (different pattern)
• AMPA receptor internalization
• Protein phosphatase activation

In AD:

• Pathological LTD enhancement
• Excessive weakening
• Memory destabilization

Homeostatic Plasticity

Synaptic Scaling:

• Global adjustment of synaptic strength
• Upregulation in response to silencing
• Downregulation in response to overactivity

AD Impairment:

• Impaired scaling responses
• Reduced plasticity
• Network instability

Synaptic Dysfunction and Cognitive Decline

Memory Circuitry

Encoding:

• LTP in hippocampus
• Cortical consolidation

Retrieval:

• Synaptic activation patterns
• Replay mechanisms

AD Defects:

• LTP impairment
• Consolidation failure
• Retrieval instability

Executive Function

Prefrontal Cortex:

• Working memory circuits
• Cognitive control networks

AD Changes:

• Synaptic loss in PFC
• Network dysfunction
• Executive impairment

Spatial Navigation

Place Cells:

• Location encoding
• Grid cell interaction

AD Effects:

• Place cell dysfunction
• Spatial memory loss
• Navigation deficits

Synaptic Biomarkers in Detail

Cerebrospinal Fluid Markers

| Marker | Source | Significance |
|--------|--------|--------------|
| Neurogranin | Postsynaptic | Synaptic loss |
| SNAP-25 | Presynaptic | Terminal damage |
| Synaptotagmin-1 | Vesicles | Release machinery |
| PSD95 | PSD | Postsynaptic integrity |

Blood-Based Markers

• Neurogranin: Detectable in blood
• SNAP-25: Emerging assays
• Synaptic vesicles: Exosome markers

Imaging Markers

SV2A PET Ligands:

• 11C-UCB-J
• 18F-GE-181
• Synaptic density quantification

FDG-PET:

• Synaptic metabolism
• Regional hypometabolism

Therapeutic Target Engagement

Amyloid-Targeting

• Anti-Aβ antibodies
• BACE inhibitors
• Aggregation inhibitors
• Vaccine approaches

Synaptic Benefits:

• Reduced toxic oligomers
• Presynaptic function
• Receptor preservation

Tau-Targeting

• Anti-tau antibodies
• O-GlcNAc modulation
• Kinase inhibitors

Synaptic Benefits:

• Reduced mislocalization
• Spine preservation
• Function restoration

Synaptic-Directed Therapies

Fyn Kinase Inhibitors:

• Prevent NMDA toxicity
• Protect spines
• Improve cognition

NMDA Modulation:

• Partial antagonists
• Glycine site modulators
• Channel blockers

Neurotrophins:

• BDNF delivery
• NGF approaches
• Receptor agonists

Summary and Future Directions

Synaptic loss represents the final common pathway of neurodegeneration in AD. Key points:

Pathological Cascade

Aβ oligomer binding to synapses

Tau mislocalization to dendrites

Receptor internalization

Calcium dysregulation

Synaptic protein degradation

Spine loss

Circuit dysfunction

Cognitive decline

Therapeutic Implications

• Early intervention critical
• Synaptic preservation essential
• Multi-target approaches needed
• Biomarker development important

Future Directions

• Single-synapse analysis
• In vivo imaging advances
• Synaptic repair strategies
• Network restoration approaches

Certain synaptic proteins are particularly vulnerable:

Synaptophysin: Most abundant synaptic vesicle protein. Early marker of synaptic loss. Conserved across species.

PSD95: Critical postsynaptic scaffold. Reduced early in AD. Key therapeutic target.

• Reduced early in AD
• Key therapeutic target

Synapsin:

• Vesicle trafficking
• Activity-dep- Calcium binding

Regional Vulnerability

Entorhinal Cortex:

• First affected region
• Layer II stellate cells
• Perforant path origin

Hippocampus CA1:

• Pyramidal neuron synapses
• Highly vulnerable
• Early tau pathology

Basal Forebrain:

• Cholinergic terminals
• Trophic support loss
• Memory circuits

Developmental Factors

• Early life experiences
• Cognitive reserve
• Education effects
• Synaptic baseline

Synaptic Resilience Factors

Protective Mechanisms

Cognitive Reserve:

• Higher baseline synapses
• Redundant circuits
• Compensatory plasticity

Lifestyle Factors:

• Physical exercise
• Cognitive engagement
• Social interaction
• Mediterranean diet

Neurotrophic Support

Brain-Derived Neurotrophic Factor (BDNF):

• Synaptic maintenance
• Spine formation
• LTP enhancement

Activity-Dependent Signaling:

• Neuronal activity promotes survival
• Use-dependent maintenance
• Network activity effects

Synaptic Imaging Advances

Electron Microscopy

Serial Section EM:

• Synaptic ultrastructure
• Spine morphology
• Contact analysis

In AD:

• Reduced contacts
• Abnormal spines
• Ultrastructural changes

Super-Resolution Microscopy

STORM/PALM:

• Nanoscale localization
• Protein clustering
• Synaptic organization

Findings:

• Receptor clustering changes
• Scaffold alterations
• Nanodomain disruption

Live Imaging

Two-Photon Microscopy:

• Spine dynamics
• Activity patterns
• Calcium imaging

In AD Models:

• Reduced spine motility
• Stability changes
• Activity alterations

Genetic Factors in Synaptic Vulnerability

AD Risk Genes

APP:

• Amyloid precursor protein
• Synaptic function normally
• Aβ generation

APOE:

• Lipoprotein E4 allele
• Synaptic repair impairment
• Increased vulnerability

TREM2:

• Microglial signaling
• Synaptic pruning regulation
• Risk variant effects

Synaptic Function Genes

SNAP29:

• SNARE complex
• Synaptic vesicle fusion
• Mutations cause disease

STXBP1:

• Munc18-1
• Synaptic release
• Developmental effects

Synaptic Dysfunction in Disease Models

In Vitro Models

Neuronal Cultures:

• Aβ oligomer application
• Tau expression
• Synaptic markers

Organotypic Slices:

• Circuit-level analysis
• Network activity
• Preservation

In Vivo Models

APP/PS1 Mice:

• Amyloid deposition
• Synaptic loss
• Behavioral correlates

Tau Models:

• Tau pathology
• Synaptic dysfunction
• Network effects

iPSC Models

Patient Neurons:

• Relevant genetics
• Disease mechanisms
• Therapeutic screening

Clinical Implications

Diagnostic Value

• Early synaptic loss detection
• Disease progression markers
• Treatment response

Therapeutic Monitoring

• Synaptic biomarkers
• Imaging endpoints
• Functional measures

Patient Stratification

• Synaptic reserve assessment
• Progression prediction
• Treatment selection

References

[selkoe2002 2002, selkoe2002](https://pubmed.ncbi.nlm.nih.gov/12445539/)

[terry1991 1991, Physical basis of cognitive alterations in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/1853497/)

[liu2023 2023, Tau pathology and synaptic loss in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37178956/)

[perlson2024 2024, Tau-based synaptic pathology in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38667333/)

[zhang2024 2024, Amyloid-β induced synaptic dysfunction through NMDA receptor trafficking](https://pubmed.ncbi.nlm.nih.gov/38734892/)

[yang2023 2023, Synaptic mitochondrial dysfunction in early AD](https://pubmed.ncbi.nlm.nih.gov/37005348/)

[shi2023 2023, Microglia complement C1q and C3 mediate synaptic pruning in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/37855670/)

[li2023 2023, Complement activation drives synaptic loss in AD mouse models](https://pubmed.ncbi.nlm.nih.gov/37612502/)

[wang2024 2024, Complement C1q binds to synapses in AD brain](https://pubmed.ncbi.nlm.nih.gov/38325741/)

[yuan2023 2023, CR3-mediated microglial phagocytosis of synapses in AD](https://pubmed.ncbi.nlm.nih.gov/37248320/)

[hong2016 2016, hong2016](https://pubmed.ncbi.nlm.nih.gov/27019227/)

[park2023 2023, Microglial phagocytosis of synapses in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36754289/)

[johnson2022 2022, A brain perivascular macrophage reveal the spatial dynamics of immune cells in Alzheimer brain](https://pubmed.ncbi.nlm.nih.gov/35694267/)

[chen2020 2020, Dendritic spine degeneration and synaptic plasticity in Alzheimer′s disease](https://pubmed.ncbi.nlm.nih.gov/32083538/)

[wu2024 2024, Dendritic spine remodeling in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38598712/)

[smith2024 2024, Dendritic spine loss in APP/PS1 mice correlates with cognitive decline](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[zhou2024 2024, Synaptic dysfunction in 5xFAD mouse model](https://pubmed.ncbi.nlm.nih.gov/39065432/)

[koffie2012 2012, koffie2012](https://pubmed.ncbi.nlm.nih.gov/22722202/)

[mecca2020 2020, Synaptic integrity in the aging brain: CSF biomarkers and cognitive performance](https://pubmed.ncbi.nlm.nih.gov/31965016/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Synaptic Loss in Alzheimer's Disease Pathway discovered through SciDEX knowledge graph analysis: